For research use only. Not for therapeutic Use.
SBI-115, identified as a TGR5 (GPCR19) antagonist, demonstrates inhibitory effects on cell proliferation in cystic cholangiocytes, decreases cholangiocyte spheroid growth rate, and lowers cAMP levels. This novel compound has potential therapeutic applications in cholangiocarcinoma treatment.
| Catalog Number | I019415 |
| CAS Number | 882366-16-7 |
| Molecular Formula | C₁₄H₁₃ClN₂O₄S |
| Purity | ≥95% |
| Target | G protein-coupled Bile Acid Receptor 1 |
| Storage | 2-8°C |
| IUPAC Name | (3-methylphenyl) 5-chloro-2-ethylsulfonylpyrimidine-4-carboxylate |
| InChI | InChI=1S/C14H13ClN2O4S/c1-3-22(19,20)14-16-8-11(15)12(17-14)13(18)21-10-6-4-5-9(2)7-10/h4-8H,3H2,1-2H3 |
| InChIKey | IJPXOPBVXVPPEW-UHFFFAOYSA-N |
| SMILES | CCS(=O)(=O)C1=NC=C(C(=N1)C(=O)OC2=CC=CC(=C2)C)Cl |
| Reference | [1]. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66(4):1197-1218. |
